Login to Your Account



Amgen Unloads 13 Molecules in $1B-plus Deal with Takeda

By Donna Young


Tuesday, February 5, 2008
Amgen Inc. is selling the Japanese rights to 13 molecules, including the FDA-approved colorectal drug Vectibix (panitumumab), to Takeda Pharmaceutical Co. Ltd. in a deal potentially worth more than $1 billion. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription